| The impact of obesity on the cardiovascular system I Csige, D Ujvárosy, Z Szabó, I Lőrincz, G Paragh, M Harangi, S Somodi Journal of diabetes research 2018 (1), 3407306, 2018 | 619 | 2018 |
| Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ... The Lancet 398 (10312), 1713-1725, 2021 | 220 | 2021 |
| Hypertension in thyroid disorders E Berta, I Lengyel, S Halmi, M Zrínyi, A Erdei, M Harangi, D Páll, EV Nagy, ... Frontiers in endocrinology 10, 482, 2019 | 166 | 2019 |
| Serum paraoxonase activity changes in uremic and kidney-transplanted patients G Paragh, L Asztalos, I Seres, Z Balogh, L Löcsey, I Kárpáti, J Mátyus, ... Nephron 83 (2), 126-131, 1999 | 121 | 1999 |
| Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage M Harangi, I Seres, Z Varga, G Emri, Z Szilvássy, G Paragh, É Remenyik European Journal of Clinical Pharmacology 60, 685-691, 2004 | 111 | 2004 |
| Association of chemerin with oxidative stress, inflammation and classical adipokines in non‐diabetic obese patients P Fülöp, I Seres, H Lőrincz, M Harangi, S Somodi, G Paragh Journal of cellular and molecular medicine 18 (7), 1313-1320, 2014 | 90 | 2014 |
| Contribution of animal models to the understanding of the metabolic syndrome: a systematic overview O Varga, M Harangi, IAS Olsson, AK Hansen Obesity Reviews 11 (11), 792-807, 2010 | 87 | 2010 |
| Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Z Balogh, I Seres, M Harangi, P Kovacs, GY Kakuk, GY Paragh Diabetes and Metabolism 27 (5; PART 1), 604-610, 2001 | 85 | 2001 |
| The human paraoxonase‐1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters HZ Mirdamadi, F Sztanek, Z Derdak, I Seres, M Harangi, G Paragh British journal of clinical pharmacology 66 (3), 366-374, 2008 | 81 | 2008 |
| The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease G Paragh, I Seres, M Harangi, Z Balogh, L Illyes, J Boda, Z Szilvássy, ... Diabetes & metabolism 29 (6), 613-618, 2003 | 72 | 2003 |
| Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels P Koncsos, I Seres, M Harangi, I Illyés, L Józsa, F Gönczi, L Bajnok, ... Pediatric research 67 (3), 309-313, 2010 | 71 | 2010 |
| Determination of DNA damage induced by oxidative stress in hyperlipidemic patients M Harangi, É Remenyik, I Seres, Z Varga, E Katona, G Paragh Mutation Research/Genetic Toxicology and Environmental Mutagenesis 513 (1-2 …, 2002 | 67 | 2002 |
| High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus K Gaál, T Tarr, H Lőrincz, V Borbás, I Seres, M Harangi, P Fülöp, ... Lipids in health and disease 15, 1-8, 2016 | 65 | 2016 |
| Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia G Paragh, D Tör’’ocsik, I Seres, M Harangi, L Illyés, Z Balogh, P Kovacs Current medical research and opinion 20 (8), 1321-1327, 2004 | 62 | 2004 |
| Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease F Sztanek, I Seres, M Harangi, L Lőcsey, J Padra, GJR Paragh, L Asztalos, ... Nephrology Dialysis Transplantation 27 (7), 2866-2872, 2012 | 55 | 2012 |
| Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity M Harangi, HZ Mirdamadi, I Seres, F Sztanek, M Molnár, A Kassai, ... Translational Research 153 (4), 190-198, 2009 | 51 | 2009 |
| Dynamic interplay between metabolic syndrome and immunity G Paragh, I Seres, M Harangi, P Fülöp Oxidative Stress and Inflammation in Non-communicable Diseases-Molecular …, 2014 | 50 | 2014 |
| Orlistat increases serum paraoxonase activity in obese patients M Audikovszky, G Pados, I Seres, M Harangi, P Fülöp, E Katona, L Illyés, ... Nutrition, metabolism and cardiovascular diseases 17 (4), 268-273, 2007 | 50 | 2007 |
| Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects H Lőrincz, M Katkó, M Harangi, S Somodi, K Gaál, P Fülöp, G Paragh, ... Clinical endocrinology 81 (3), 370-377, 2014 | 49 | 2014 |
| The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation P Szodoray, G Papp, B Nakken, M Harangi, M Zeher Autoimmunity Reviews 9 (6), 459-464, 2010 | 47 | 2010 |
György ParaghUniversity of Debrecen, Medical and Health Science CentreEmail verificata su internal.med.unideb.hu